Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

Exclusion Criteria

• •medium or above ascites
• •Patient of second primary tumor or multiple primary cancer
• •Patients of T cell lymphoma、myeloma,and patients are using immunosuppressant
• •Systemic autoimmune diseases, allergic constitution or immunocompromised patients
• •Patients of chronic diseases need immune stimulant or hormone therapy
• •Patients of active bleeding or coagulant function abnormality（PT\>16s、APTT\>43s、TT\>21s、INR≥2）,and patients of bleeding tendency or are receiving thrombolysis and anticoagulation and antiplatelet therapy
• •Women who is pregnant or during breast feeding or plan to pregnant in 2 years,and not willing to contraception during the test
• •Patients with brain、dura mater metastases or history of psychogenic
• •Gastrointestinal bleeding in the past six months or have clear gastrointestinal bleeding tendency,such as: patients of local active ulcerative lesions, defecate occult blood + + above shall not enter into group; defecate occult blood + depend on gastroscopy
• •Patients with severe stomach/esophageal varices and need for intervention treatment
• •Patients with abdominal fistula, gastrointestinal perforation or abdominal abscess within 4 weeks before the first treatment
• •Positive for HIV antibody
• •Patients who are allergic to computed tomography (CT) and magnetic resonance imaging (MRI) contrast agents at the same time, can't imaging assay
• •Patients accepted any experimental drugs or pilot medical apparatus and instruments in the past 4 weeks of first treatment
• •Other reasons the researchers think not suitable